Total Payments
$373,256
2024 Payments
$47,816
Companies
34
Transactions
832
Medicare Patients
3,137
Medicare Billing
$797,020
Payment Breakdown by Category
Other$308,460 (82.6%)
Travel$35,639 (9.5%)
Food & Beverage$20,752 (5.6%)
Consulting$8,168 (2.2%)
Education$237.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $244,659 | 125 | 65.5% |
| Honoraria | $36,407 | 15 | 9.8% |
| Travel and Lodging | $35,639 | 146 | 9.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $27,395 | 11 | 7.3% |
| Food and Beverage | $20,752 | 520 | 5.6% |
| Consulting Fee | $8,168 | 7 | 2.2% |
| Education | $237.64 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | $90,366 | 129 | $0 (2024) |
| Merck Sharp & Dohme LLC | $77,657 | 160 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $47,534 | 55 | $0 (2024) |
| Melinta Therapeutics, LLC | $32,988 | 124 | $0 (2024) |
| Shionogi Inc | $32,576 | 61 | $0 (2024) |
| Allergan, Inc. | $20,827 | 51 | $0 (2020) |
| La Jolla Pharmaceutical Company | $19,547 | 40 | $0 (2024) |
| Medtronic Vascular, Inc. | $14,424 | 26 | $0 (2019) |
| TETRAPHASE PHARMACEUTICALS, INC. | $11,961 | 30 | $0 (2020) |
| The Medicines Company | $10,255 | 34 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,816 | 101 | Shionogi Inc ($18,157) |
| 2023 | $69,950 | 129 | Takeda Pharmaceuticals U.S.A., Inc. ($40,056) |
| 2022 | $44,974 | 119 | Paratek Pharmaceuticals, Inc. ($30,255) |
| 2021 | $37,135 | 88 | Paratek Pharmaceuticals, Inc. ($31,642) |
| 2020 | $2,849 | 24 | Merck Sharp & Dohme Corporation ($2,517) |
| 2019 | $49,337 | 93 | Merck Sharp & Dohme Corporation ($33,704) |
| 2018 | $68,710 | 140 | Melinta Therapeutics, Inc. ($30,495) |
| 2017 | $52,484 | 138 | Allergan Inc. ($14,443) |
All Payment Transactions
832 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/12/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $281.25 | General |
| Category: ANTIFUNGALS | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $34.52 | General |
| Category: Infectious Diseases | ||||||
| 12/02/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: ANTIBIOTIC | ||||||
| 11/27/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 11/15/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/29/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: ANTIBIOTIC | ||||||
| 10/29/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/22/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: ANTIBIOTIC | ||||||
| 10/15/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $30.50 | General |
| Category: GI | ||||||
| 10/09/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,605.00 | General |
| Category: ANTIBIOTIC | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), ZERBAXA, DIFICID | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/03/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | In-kind items and services | $802.10 | General |
| Category: ANTIBIOTIC | ||||||
| 10/03/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | In-kind items and services | $720.95 | General |
| Category: ANTIBIOTIC | ||||||
| 10/03/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | In-kind items and services | $406.12 | General |
| Category: ANTIBIOTIC | ||||||
| 10/03/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $108.58 | General |
| Category: ANTIBIOTIC | ||||||
| 10/03/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | Cash or cash equivalent | $87.40 | General |
| Category: ANTIBIOTIC | ||||||
| 10/03/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | Cash or cash equivalent | $60.46 | General |
| Category: ANTIBIOTIC | ||||||
| 09/24/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/24/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/10/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Respiratory | ||||||
| 08/27/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: ANTIFUNGALS | ||||||
| 08/13/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/06/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 812 | 4,704 | $841,745 | $296,462 |
| 2022 | 8 | 659 | 1,862 | $529,400 | $158,255 |
| 2021 | 8 | 753 | 1,976 | $564,875 | $166,868 |
| 2020 | 9 | 913 | 2,287 | $630,858 | $175,435 |
Total Patients
3,137
Total Services
10,829
Medicare Billing
$797,020
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 47 | 493 | $197,200 | $83,375 | 42.3% |
| J2406 | Injection, oritavancin (kimyrsa), 10 mg | Office | 2023 | 15 | 2,280 | $148,200 | $74,144 | 50.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 255 | 946 | $236,500 | $58,221 | 24.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 133 | 386 | $135,100 | $36,106 | 26.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 136 | 141 | $38,775 | $14,302 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 124 | $18,700 | $11,504 | 61.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 56 | $22,400 | $7,477 | 33.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 137 | $30,825 | $6,558 | 21.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 41 | $4,150 | $2,752 | 66.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 27 | 41 | $6,150 | $1,528 | 24.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 42 | $3,150 | $482.99 | 15.3% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 14 | 17 | $595.00 | $13.21 | 2.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 262 | 829 | $207,250 | $46,857 | 22.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 17 | 210 | $84,000 | $37,128 | 44.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 105 | 445 | $155,750 | $36,493 | 23.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 148 | 157 | $43,250 | $16,581 | 38.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 119 | $17,850 | $10,769 | 60.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 30 | 30 | $12,000 | $4,785 | 39.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 58 | $5,800 | $3,952 | 68.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $3,500 | $1,689 | 48.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 124 | 605 | $211,750 | $50,554 | 23.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 300 | 805 | $201,250 | $46,230 | 23.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 14 | 129 | $51,600 | $23,388 | 45.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 187 | 201 | $55,275 | $21,881 | 39.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 168 | $25,200 | $17,062 | 67.7% |
About Dr. Christopher Cooper, MD
Dr. Christopher Cooper, MD is a Infectious Disease healthcare provider based in Altamonte Springs, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1154321057.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Cooper, MD has received a total of $373,256 in payments from pharmaceutical and medical device companies, with $47,816 received in 2024. These payments were reported across 832 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($244,659).
As a Medicare-enrolled provider, Cooper has provided services to 3,137 Medicare beneficiaries, totaling 10,829 services with total Medicare billing of $797,020. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Altamonte Springs, FL
- Active Since 07/21/2005
- Last Updated 10/17/2013
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1154321057
Products in Payments
- NUZYRA (Drug) $90,366
- ZERBAXA (Drug) $49,953
- LIVTENCITY (Drug) $46,570
- Fetroja (Drug) $28,436
- Vabomere (Drug) $21,816
- DIFICID (Drug) $21,767
- XERAVA (Drug) $16,636
- Xerava (Drug) $11,912
- AVYCAZ (Drug) $9,697
- DALVANCE (Drug) $9,438
- Baxdela (Drug) $7,170
- VABOMERE (Drug) $6,501
- ZINPLAVA (Biological) $5,711
- Cresemba (Drug) $4,121
- ORBACTIV (Drug) $3,754
- CRESEMBA (Drug) $3,316
- XACDURO (Drug) $2,961
- Orbactiv (Drug) $1,842
- TEFLARO (Drug) $1,685
- Arikayce (Drug) $1,437
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Altamonte Springs
Dr. Juan Diaz, D.o, D.O
Infectious Disease — Payments: $1.1M
Infectious Disease $1.1M
Jason Sniffen, Do, DO
Infectious Disease — Payments: $459,299
Infectious Disease $459,299
Fernando Alvarado, Md, MD
Infectious Disease — Payments: $16,125
Infectious Disease $16,125
Javier Marinez, Md, MD
Infectious Disease — Payments: $7,961
Infectious Disease $7,961
Dr. Anibal Maldonado, M.d, M.D
Infectious Disease — Payments: $4,049
Infectious Disease $4,049
Joseph Katta, Do, DO
Infectious Disease — Payments: $2,143
Infectious Disease $2,143